A mutation in the gene coding for epidermal growth factor receptor (EGFR) is common in NSCLC patients (found in 10%–30% of patients), and downstream signaling pathways such as MAPK/ERK, PI3K/AKT and Bax/Bcl-2 are also potential targets (11). Here, AKT1 is linked to non-small cell lung carcinoma.